Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

This study has been completed.
Information provided by:
Anthera Pharmaceuticals Identifier:
First received: September 4, 2007
Last updated: January 3, 2008
Last verified: January 2008
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: December 2007
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by Identifier (NCT Number):